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ABBREVIATIONS. HBPV, Haemophilus influenzae type b poly-
saccharide vaccine; ICD-9, International Classification of Dis-
eases, ninth revision.
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ABSTRACT. The Haemophilus influenzae type b polysac-
charide vaccine was licensed for use in the United States
in April 1985. Postlicensure case-control efficacy studies
have yielded markedly different estimates of efficacy,
leading to contradictory recommendations to practicing
physicians. To obtain additional information about the
efficacy of the vaccine, we studied cases of invasive Hae-
mophilus influenzae type b disease ascertained through
active surveillance in areas with a total population of 34
million. We enrolled children 24 to 59 months of age who
did not attend day-care centers. (Data from our day-care
study have been published elsewhere.) For each case
child, as many as three 24- to 59-month-old control
children were chosen from a roster of acquaintances
supplied by the child’s parent. Conditional logistic regres-
sion was used, and vaccine efficacy was estimated to be
62% (95% confidence interval = 0%, 85%), which did not
change significantly after adjusting for age and parental
smoking, variables that were significantly different for
case and control children. Results of this study support
our previous finding of a positive protective efficacy,
albeit lower than the efficacy of 90% found in children
18 to 71 months of age in the Finnish prelicensure trial.
Pediatrics 1989;84:255-261; Haemophilus influenzae type
b polysaccharide vaccine.
ysaccharide vaccine (HBPV).’3 Although a large
clinical trial in Finland in the middle 1970s dem-
onstrated clinical protective efficacy of 90% (95%
confidence interval = 55%, 98%) in children 18 to
71 months of age,4 postlicensure case-control effi-
cacy studies, including one conducted by the Cen-
ters for Disease Control,58 yielded estimates of
efficacy ranging from -69% to 88%. Interpretations
of these data have resulted in contradictory rec-
ommendations to practicing physicians9 (Ped-
Comm: American Academy of Pediatrics Member
Alert, November 13, 1987). Because of the devel-
oping controversy and our finding of a lower than
expected efficacy in our first study,5 we initiated an
additional, independent study to address the issue
of HBPV efficacy in children 24 to 59 months of
age. The study started in October 1986 and included
patients from our active surveillance system who
had a positive sterile-site culture result between
January 1 and December 31, 1986 and who had not
been eligible for our day-care-based HBPV efficacy
study.
There has been much debate recently about the
efficacy of the Haemophilus influenzae type b pol-
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METHODS
Active surveillance for invasive H influenzae type
b disease. Active surveillance for several infectious
diseases was established on January 1, 1986 in Los
Angeles County and in Missouri, New Jersey, Okla-
homa, Tennessee, and Washington, areas with a
combined population of approximately 34 million.
Details of this surveillance system have been de-
scribed elsewhere.5 Briefly, after a promotional
period, all acute-care hospitals were requested to
participate. Beginning in January 1986, biweekly
telephone calls were placed to each hospital to
solicit reports of all patients with sterile-site cul-
tures positive for H influenzae, type b.
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Data collected on each patient with H influenzae
type b isolated from a normally sterile site included
name, address, age, date of admission, clinical syn-
drome (eg, meningitis, epiglottitis), the sterile site
from which the organism was isolated, and sero-
type. Directors of hospital laboratories were re-
quested to submit to the Centers for Disease Con-
trol isolates of H influenzae type b collected from
sterile sites in patients with clinical findings con-
sistent with H influenzae type b infection. Serotype
data came from three sources: hospital, state, and
the Centers for Disease Control laboratories.
Estimates of total population and population <5
years of age were obtained from the US Census
Bureau for July 1, 1986, with the exception of Los
Angeles County, for which the population <5 was
not available. This was estimated by applying the
proportion of the total population that was <5 years
of age for the last year that age-specific data were
available (1984) to the total population of the
county in 1986.
Evaluation of Completeness of Surveillance.
To assess the sensitivity of active surveillance,
we reviewed International Classification of Diseases,
revision 9 (ICD-9) discharge diagnoses for H influ-
enzae. Except for several hospitals that declined to
participate, this was done for all hospitals in Los
Angeles County, Missouri, Tennessee, and Wash-
ington; a systematic sample of one half of all hos-
pitals in Oklahoma; and for no hospitals in New
Jersey. The sensitivity of surveillance for New Jer-
sey is currently being determined directly by review
of hospital laboratory records. Codes reviewed were
038.41 (H influenzae septicemia) and 320.0 (H in-
fluenzae meningitis). Patients identified through
ICD-9 information had their medical records re-
viewed to determine whether H influenzae type b
had been isolated from a normally sterile body fluid.
Sterile-site positive cases were then compared with
cases reported through active surveillance. The sen-
sitivity of surveillance was estimated as the propor-
tion of cases identified by ICD-9 review that had
also been reported through active surveillance.
Selection of Case Children
A child was considered eligible if he or she was
24 to 59 months of age, had H influenzae type b
isolated from any site normally considered to be
sterile in conjunction with clinical signs of infec-
tion, did not attend day-care (defined as any super-
vised care of at least two unrelated children for at
least 4 h/wk) in the week before the positive H
influenzae type b culture, and lived in a surveillance
area. Eligibility also required that the date of posi-
tive culture for H influenzae type b be between
January 1 and December 31, 1986. The lower age
limit was chosen because children <24 months of
age who are not in day care are generally not eligible
for HBPV. The upper cutoff (<60 months of age)
is consistent with the Immunization Practices Ad-
visory Committee recommendations for HBPV
usage.’#{176}
A consent statement was obtained from and a
screening questionnaire was administered to par-
ents of all children who met the age criteria to
determine day-care status and willingness to par-
ticipate. Children not in day care were enrolled. A
questionnaire was completed for each eligible pa-
tient by interviewing one of the child’s parents or
guardians.
Data collected for each case child included de-
mographic and socioeconomic variables, type of
health cane provider (private vs public), and HBPV
status. Vaccination status was verified for all case
children by interviewing each child’s health care
provider while the provider had the child’s medical
record in hand. Only children who had been vacci-
nated 14 days before the date of hospital admis-
sion or date of positive culture result were consid-
ered to be vaccinated. Additional data obtained for
each vaccinated child included date of vaccination,
brand of HBPV administered, lot number, concur-
rent diphthenia-tetanus-pertussis vaccine adminis-
tration, and reported adverse reactions to HBPV.
In addition, physicians were asked about any un-
derlying disease that might predispose the child to
serious infection, regardless of vaccination status.
Selection of Control Children
Control children were selected from a roster of
acquaintances obtained from the case child’s par-
ent. Parents were asked to provide a list of all
acquaintances living in the study area on the case
date of admission who might have children aged 24
to 59 months. Parents were unaware of the study
hypothesis, and HBPV was not mentioned until the
list of potential control children had been obtained.
Parents of potential control children were con-
tacted to determine whether their children were
eligible, using the same age and day-care criteria
applied to case children. As many as three control
children were chosen for each case child; control
children were matched to case children based on
closeness in age. Control children were not permit-
ted to be siblings of each other; if siblings were
listed as potential control children, only the sibling
closest in age to the case child was selected. The
same information collected for the case child was
collected for each eligible control child. The verifi-
 
TABLE 1. Invasive Haemophilus influenzae Type b
Disease in Children Less Than 5 Years of Age, by Study
Area, 1986
Area Total No. of
Children
With Disease
198
311
203
255
263
Population
<5 y of
Age
499 000
676 000
327 000
370 000
339000
Rateper 100000
Children <5 y of
Age_____
40
46
62
69
78
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cation of vaccination status form was completed for
each control child while the health care provider
had the child’s medical record in hand.
Laboratory Methods
All sterile-site isolates of H influenzae type b
received by the Centers for Disease Control were
characterized serologically by slide agglutination
with the use of H influenzae polyvalent capsular
antiserum and type-specific antiserum prepared at
the Centers for Disease Control for capsule types a
through f.
Statistical Methods
Conditional logistic regression was used for sta-
tistical analysis.” This method, which is designed
for matched studies, can be used to adjust for mul-
tiple confounding variables, as well as to evaluate
effect modification. In our study, age was a poten-
tial confounder because it is related to both the
disease and the likelihood of vaccination. Because
we did not closely match children’s ages, case chil-
dren were younger than control children. To handle
this potential problem, vaccine efficacy estimates
were age adjusted by including a linear term for age
in months in all models. This corrects for age
differences of 1 month between case and control
children. Estimates of vaccine efficacy were calcu-
lated using the formula VE = 1 - matched odds
ratio. Differences in vaccine efficacy were evaluated
with a likelihood ratio test.
RESULTS
Rates of Invasive H influenzae Type b Disease
A total of 1444 cases of invasive H influenzae
type b disease in children <5 years of age were
reported from the six surveillance areas during 1986
(Table 1). The overall rate of invasive H influenzae
type b disease was 58/100 000 per year in children
<5 years of age. Rates by area ranged from 40/
100000 for New Jersey to 80/100000 for Okla-
homa.
Review of ICD-9 discharge diagnoses for all areas
except New Jersey detected 445 sterile-site-positive
cases in children <60 months old admitted during
1986. Although this was fewer than the number of
cases detected through active surveillance (1444),
these ICD-9 cases were use to estimate the sensitiv-
ity of active surveillance. Of the 445 cases, 406 were
reported through active surveillance, giving an
overall estimated sensitivity for invasive H influ-
enzae type b disease in children <5 years old of 91%
(95% confidence interval = 88%, 94%). Including
only those children 18 to 59 months of age, 109 of
New Jersey
Los Angeles
Tennessee
Missouri
Washing-
ton
Oklahoma 214 267000 80
All areas 1444 2 478 000 58
123 cases, or 89%, were detected (95% confidence
interval = 83%, 95%). There were an additional
eight case children identified through discharge
diagnoses for whom age was not known and who
were not identified through active surveillance.
Case and Control Children
Of the 1444 case children identified through ac-
tive surveillance, 244 met our age criteria. Day-care
status was known for 239 children, or 98%. Of these,
128 (54%) were not in day care. For 109 (85%) of
these children, parents were contacted and inter-
viewed and vaccination status verified. Enrollment
was higher for case children with dates of culture
during the last 6 months of 1986 (62 of 65 eligible
case children enrolled [95%]) than during the first
6 months (47 of 63 case children [75%]) (P = .002).
This was because the study was initiated in October
1986, and many ofthe children with cases of disease
that had occurred during the first 6 months of the
year had moved by that time. Of the 109 children
for whom parents could be contacted, 74 (68%) had
age-matched control children and thus were in-
cluded in the matched analysis. Reasons why con-
trol children could not be identified for 35 case
children included failure of case parents to identify
acquaintances with children eligible for the study,
refusal of case parents to provide a list of acquaint-
ances, and inability to locate acquaintances pro-
vided by case parents. There were a total of 129
control children; vaccination status was available
for 127. Thirty-seven case children (50%) had 1
control child, 19 (26%) had 2 control children, and
18 (24%) had 3 control children.
Vaccination Status and Analysis of
Questionnaire Variables
Of the 74 case children with control children, 9
(12%) had received HBPV compared with 28 of 127
(22%) control children.
Variables that were associated with vaccination
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in the control children included total family income
$20 000/y (69% for vaccinated control children vs
39% for unvaccinated control children, P = .08,
Fisher’s exact test, two-tailed) and mean years of
maternal education, P = .02, Wilcoxon rank-sum
test, two-tailed). However, when case and control
children were compared by these and other poten-
tially confounding variables (Table 2), only age
(average 33.9 months for case children vs 37.2
months for control children (matched odds ratio =
0.96, 95% confidence interval = 0.92, 0.99, condi-
tional logistic regression) and parental smoking
(more common in case children, matched odds ratio
= 2.37, 95% confidence interval = 1.17, 4.82) were
significantly different.
An unmatched comparison of vaccinated case
children and control children by injection site, con-
current administration of diphtheria-tetanus-per-
tussis vaccine, and type of vial (single vs multidose)
showed no significant differences between the two
groups.
Vaccine Efficacy
Before the data were adjusted for differences in
age and parental smoking, vaccine efficacy (crude
vaccine efficacy) was 64%. After adjusting for age
and parental smoking, vaccine efficacy was esti-
mated to be 62% (95% confidence interval = 0%,
85%).
Three of 33 (9%) case children without control
children had been vaccinated, which was not sig-
nificantly different from the rate of vaccination of
case children with control children (12%). However,
because both the rate ofvaccination ofcase children
and control children determines the estimate of
vaccine efficacy, we compared the case children
with control children to those without control chil-
dren for six socioeconomic variables (Table 3). Al-
though several differences were found, none was of
substantial magnitude, and none was statistically
significant.
There was not a statistically significant differ-
ence in efficacy between children 24 to 35 months
of age (50 case children with control children) and
36 to 59 months of age (24 case children with
control children), although the statistical power to
detect a difference was limited. Sample sizes for the
six study areas were inadequate to estimate efficacy
by area.
When vaccine efficacy was analyzed by clinical
syndrome, efficacy for meningitis (38 cases), epi-
glottitis (16 cases), and all other infections (20
cases) was 91% (95% confidence interval = -2 1%,
99%), 57% (95% confidence interval = -352%,
96%), and -14% (95% confidence interval =
-466%, 77%), respectively. The “other” category
included primary bacteremia (15 cases), pneumonia
(2 cases), cellulitis (2 cases), and both cellulitis and
arthritis (1 case). The differences in vaccine effi-
cacy by syndrome were not statistically significant
(P = .19). In addition, there were no significant
TABLE 3. Case Children With Controls
With Case Children Without Controls in the
trol Study of Vaccine Efficacy
Compared
Case-Con-
Variable Case Children P
. .With Without
Value
Controls Controls
(n=74) (n=35)
Sex (% boys) 55 29 0.15*
Race (%)
White 71 64 #{216}5#{216}*
Nonwhite 29 36
Income >$20 000 (%) 52 38 0.27*
Age (mo) 33.9 36.7 0.07t
Maternal education (y) 12.0 11.1 0.13t
Rooms in house (No.) 5.5 5.1 0.22t
* Fisher’s exact test.
t Wilcoxon rank-sum test.
TABLE 2. Possible Confounding Variables in the Case-Control Study of Vaccine
Efficacy
Variable Case Control Children Matched 95%
Children (n = 127) Odds Confidence
(n = 74) Ratio Interval
(%)
Sex (% boys) 55 52 1.24 0.67, 2.33
Race (%)
White 71 78 0.71 0.14, 3.59
Nonwhite 29 22 1.00
Income >$20 000 (%) 52 46 1.35 0.68, 2.69
Age (mo) 33.9 37.2 0.96 0.92, 0.99
Maternal education (y) 12.0 12.2 1.02 0.86, 1.20
Rooms in house (No.) 5.5 5.7 0.96 0.76, 1.21
Parental smoking (%) 50 35 2.37 1.17, 4.82
Breast-feeding (%) 47 61 0.56 0.27, 1.15
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differences in the distribution of cases by syndrome
among case children with control children, case
children contacted but without control children,
and case children who could not be contacted.
To determine whether the inclusion of case chil-
dren with positive culture results during months of
low enrollment biased our estimate of efficacy, we
estimated vaccine efficacy for the first 6 months of
the year (enrollment of 75%) and for the last 6
months (enrollment of 95%). The resulting esti-
mates were 74% and 55%, respectively; the differ-
ence was not statistically significant (P = .58).
To measure the potential bias of the approxi-
mately 10% underreporting in our active surveil-
lance system, we recalculated vaccine efficacy after
increasing the number of case children by 10%; we
assumed that all of these children were unvaccin-
ated, because reporting bias, if any, would most
likely favor the identification of vaccinated chil-
dren. Unmatched vaccine efficacy in this hypothet-
ical example was estimated to be 62%. Because the
sensitivity of active surveillance is unknown for
New Jersey, we reanalyzed the data excluding case
children and control children from this state and
estimated efficacy to be 56% (95% confidence in-
terval = -4%, 83%).
We assessed the effectiveness of the age adjust-
ment by calculating vaccine efficacy for case chil-
dren with tightly age-matched control children. An
age-matched control child is within the same pre-
determined age stratum (24 to 35 and 36 to 59
months of age) as a case child. Vaccine efficacy in
this analysis was 58% (95% confidence interval =
-37%, 87%), suggesting that our model did not
change the point estimate of efficacy but did in-
crease the statistical power.
To exclude the potential bias of selective vacci-
nation of children with illnesses that predispose to
invasive H influenzae type b disease, we excluded
from the analysis three case children (one each with
a bone marrow transplant, a renal transplant, and
thalassemia) and one control child (with an un-
specified malignancy) reported by their physicians
as having an underlying disease. Vaccine efficacy
was 70% (95% confidence interval = 17%, 89%).
The Centers for Disease Control received and
serotyped H influenzae type b strains for 49 (66%)
of the 74 patients with matched control children.
All of the strains were serotype b. An additional 15
case children (20%) either had serotyping done by
hospital or state laboratories or had positive anti-
gen detection for H influenzae type b. Serotype
information was not available for 10 (14%) case
children. Although >95% of invasive H influenzae
type b strains in children are serotype b, we ana-
lyzed our data excluding the case children for whom
serotype information was not available. Vaccine
efficacy was 62% (95% confidence interval = -4%,
87%), identical with our original point estimate.
Risk of Invasive H Influenzae Type b Disease
During Week Following Vaccination
To address the issue of the risk of H influenzae
type b disease in the 7-day period following immu-
nization, we determined the number of case chil-
dren and control children who had received HBPV
within 7 days before the case date of admission.
Only one case child and no control children fit this
criterion.
DISCUSSION
The decision to license HBPV in the United
States in April 1985 was based on one randomized
clinical trial that demonstrated an efficacy of 90%
(95% confidence interval = 55%, 98%) in children
18 to 71 months of age.4 Because randomized, con-
trolled trials were no longer ethically feasible after
licensure, it became necessary to develop alterna-
tive methods for monitoring HBPV efficacy. A
number of investigators resorted to case control
studies.5
All studies to date, except one, have demon-
strated positive efficacy, with individual point es-
timates ranging from 41% to %#{149}58 The one study
with a negative point estimate (-69%) had a small
sample size and had broad 95% confidence limits
(-415%, 33%)#{149}8 Several possible explanations for
the wide range in efficacy estimates have been
raised, including regional differences in efficacy;
until the biologic plausibility of this hypothesis is
demonstrated, it must be considered speculative.
A computer simulation of the range of efficacy
estimates expected from studies of a similar size to
those conducted showed that, if the true efficacy
were 50%, a wide range of study results similar to
that observed would be expected.3 This points out
the problem of limited statistical precision in small
case-control studies for vaccines oflow efficacy. For
example, even though 126 case children and 291
control children were enrolled in our day-care-
based HBPV efficacy study (the larger of our two
studies) that estimated an efficacy of 45%, our 95%
confidence limits were relatively wide (-1%, 70%).
Had the true efficacy been 75% to 90%, which is
the range of efficacies we used to calculate the
expected sample size for that as well as the present
study, our confidence limits would have been much
narrower.
The finding of parental smoking as a risk factor
for primary H influenzae type b disease (matched
odds ratio = 2.37; 95% confidence interval = 1.17%
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4.82%) is difficult to interpret, given that our pre-
vious study of risk factors for H influenzae type b
disease’2 did not find this association, nor did a
review of unpublished data from our earlier HBPV
efficacy study.5 However, several studies have in-
dicated a link between passive exposure to cigarette
smoke and upper respiratory tract infections in
children.’3’5 Whether such exposure is truly a risk
factor for invasive H influenzae type b disease will
need to be evaluated in future studies.
Like all case-control studies, our study might
have biases that could affect our results. For ex-
ample, because we began this study 9 months into
1986, we could not contact some of the children
who had had disease that occurred earlier in the
year. However, the fact that efficacy was not sig-
nificantly different for months with incomplete en-
roliment compared with months with good enroll-
ment suggests that incomplete enrollment did not
bias our estimate of efficacy.
In addition, exclusion from the matched analysis
of the 35 case children without control children
could have affected our estimate. Two facts, how-
ever, suggest that this is not the case. First, the rate
of vaccination of the 35 case children who were
contacted but did not have controls (9%) was not
significantly different from the 74 case children
with control children (12%). Second, the case chil-
dren without control children did not differ signif-
icantly from the case children with control children
when compared for variables that affect the likeli-
hood of vaccination (Table 3). This suggests that,
had we been able to obtain matched acquaintance
control children for these case children, their rate
of vaccination would not have differed from the
rate of vaccination of our 129 actual matched ac-
quaintance control children. This is important, be-
cause both the rate of vaccination of case children
and control children is used to calculate vaccine
efficacy.
Our previous HBPV efficacy study permitted us
to examine the hypothesis that there may be a
slightly increased risk of invasive H influenzae type
b disease in the 7 days following immunization,8
and we found no significant association.5 Unfortu-
nately, we do not have enough data in the present
study to evaluate this hypothesis.
The true efficacy of HBPV has been actively
debated. Nevertheless, four of five studies suggest
that the vaccine is effective, albeit less so than
anticipated. It should be kept in mind, however,
that HBPV was introduced as an interim vaccine.
In fact, the next-generation vaccine, a polysaccha-
ride-diphtheria toxoid conjugate, has just been li-
censed for use in children 18 months of age.’6
Hopefully it will be more efficacious than HBPV in
children 18 months old; it may eventually be
licensed for use in infants, who are at highest risk
for invasive H influenzae type b disease.’7
Because licensure of the conjugate vaccine for
use in children 18 months of age is based on
immunogenicity data and comparisons with the
recent Finnish trial, postlicensure case-control ef-
ficacy studies of the conjugate vaccine are war-
ranted. In addition, the unproven hypothesis that
there may be a slight increase in the risk of invasive
H influenzae type b disease following vaccination
with HBPV should be evaluated.5’8 However, the
current controversy concerning the efficacy of
HBPV points out the limitations of individual post-
licensure case-control vaccine efficacy studies and
the need for caution in their interpretation.
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LISTERIOSIS
Listeria monocytogenes-an uncommon human pathogen of animal origin-
has some unusual properties. The organism is widespread in the environment
and many animals, and has the ability to grow over a temperature range
(2-42#{176}C) that includes refrigerator temperatures. . . . The bacterium itself be-
comes intracellular and has an outstanding predilection for pregnant women,
in whomit causes very slight or inapparent illness but may cross the placenta
to kill the fetus or give rise to perinatal septicaemia or meningitis in the
newborn baby. ...
Listeria spp are present in vegetation, water, soil, and the faeces of man and
animals, so it is not surprising that they are present in food. It follows that
ingestion of modest numbers of listenia causes no clinical problems in healthy
people. . . . The infective dose is also unknown, but presumably it is lower for
pregnant and immunologically compromised individuals than for the normal
population. ...
What is very clear is that as produced, processed, and finally cross-contami-
nated in chicken packing plants, very nearly all chicken carcasses are contam-
mated with listenia, as well as with Campylobacter jejuni and salmonellae. In
the past two or three years infections due to these microbes have increased
almost exponentially; they are all sporadic in distribution, and all three orga-
nisms are frequently introduced into the environment of the domestic kitchen
via chicken meat. ...
There is always complacency in the livestock industry when infective agents
do not cause significant economic losses in flocks or herds-listeria, salmonellae,
and campylobacters all fail to do this. Surely it is time to think of the effect on
human beings.
From Listeriosis. Lancet. 1989;1:83-84.
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